Endocrinology

An ACC board member explains the major cardiology college's decision to move the meeting online during the COVID-19 pandemic.

The Mount Sinai expert and ACC late-breaking presentation panelist highlights her most anticipated trial data and discussions in the upcoming meeting.

A new study of more than 30k Swedish men is shedding light on associations between early puberty and risk of T2D.

Muthiah Vaduganathan, MD, MPH, discusses how research of the add-on drug class will continue to evolve into 2021.

What's known about at-risk cardiometabolic patient care during the pandemic.

A discussion with a Brigham and Women's Hospital cardiologist on the research of the add-on cardiometabolic drug class.

Technology, data, and community partnerships can help improve the overall health of patients with chronic health conditions.

Telehealth tools can identify someone whose symptoms are worsening and connect them to a medical professional.

Digital tools like electronic health records play an important role in addressing care for patients with chronic health conditions.

Roy Schoenberg, MD, MPH, discusses the populations that can most benefit from using telehealth tools and Medicare reimbursement obstacles.

Endometriosis risk indicators are apparent at early ages, which could speed up diagnosis and treatment of the condition.

A new study is diving into differences in long-term outcomes, including remission rates and weight loss, seen among patients undergoing RYGB and SG.

A 6-year-old girl was brought to her pediatrician for vaginal bleeding, breast enlargement, brown patches on her cheeks, back, and trunk. Can you diagnose this patient?

An analysis of 180,000 patients in South Korea is shedding new light on the potential poor oral hygiene can have on a person's risk of diabetes.

With approval, the GLP-1 receptor agonist becomes the first diabetes drug approved for reducing MACE in patients with and without established cardiovascular.

A look back on the biggest discussions of the 29th Annual Cardiovascular Conference in Beaver Creek, CO.

A new analysis is revealing more about how using a patient portal can aid in medication adherence and HbA1c management among diabetics.

Researchers writing in Diabetes Care this month report that empagliflozin, a sodium–glucose cotransporter 2 inhibitor (SGLT2), successfully reduced liver fat content in recent-onset and metabolically well-controlled type 2 diabetes (T2D).

Medicaid expansion under the Patient Protection and Affordable Care Act (ACA) was associated with reduced uninsured rates in the diabetes belt compared with non-belt counties, say researchers writing in Diabetes Care.

New research from the American Stroke Association's International Stroke Conference indicates the presence of diabetic retinopathy was associated with increased stroke risk.

In post-myocardial infarction patients, chronically impaired renal failure and diabetes are both associated with an increased mortality risk, say researchers recently writing in Diabetes Care.

David Lee, MD, of NYU School of Medicine, discusses barbershop initiatives and how they can impact the health care of a community as a whole.

Neither intermittent nor daily dosing of vitamin D alone was associated with reduced risk of fracture, but daily supplementation with both vitamin D and calcium showed promise in a study recently published in JAMA Network Open.

A meta-analysis of CREDENCE, DECLARE-TIMI 58, CANVAS, and EMPA-REG OUTCOME trial is revealing more about how SGLT2 inhibition impacts different subgroups of diabetics.

Leading experts on nutrition and diabetes are recommending that patients still continue to follow current nutritional recommendations by the American Diabetes Association and other healthcare and governmental organizations that recommend consuming a diet rich in fruits and vegetables, while limiting red and processed meats.

Probiotic supplementation using a mix of three Lactobacillus strains naturally occurring in the human gut microbiota protects against lumbar spine bone loss in healthy, early postmenopausal women, say researchers recently writing in The Lancet Rheumatology.

An oral tablet combining empagliflozin, linagliptin, metformin hydrochloride will soon be available on US markets.

A new analysis of more than 125,000 found no differences in mortality or MACE based on type of insulin used.

The GLP-1 agonist now has indications for the reduction of MACE and the management of A1C in patients with type 2 diabetes.

A recent analysis of participants in the NHANES database found low fat and Mediterranean diets were linked to lower serum testosterone levels in men.